CCCC
C4 Therapeutics, Inc.
There isn't enough reported data to score CCCC yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CCCC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
CCCC's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CCCC PE Valuation
CCCC has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CCCC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect CCCC's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CCCC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.63 | +$1.05 |
| Q2 2026 | -$0.91 | +$0.68 |
| Q1 2026 | -$1.10 | +$0.38 |
| Q4 2025 | -$1.27 | +$0.25 |
| Q3 2025 | -$1.68 | +$0.02 |
| Q2 2025 | -$1.59 | +$0.31 |
| Q1 2025 | -$1.48 | +$0.89 |
| Q4 2024 | -$1.52 | +$1.15 |
CCCC is still losing money, but far less than before: $0.63 per share over the past year, against $8.62 at its worst in early 2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CCCC on earnings quality, reporting a profit while its opponent remains loss making.
CCCC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.5M | -25% |
| Q2 2026 | $6.6M | +2.8% |
| Q1 2026 | $6.2M | -15% |
| Q4 2025 | $11M | +113% |
| Q3 2025 | $11.2M | -27% |
| Q2 2025 | $6.5M | -46% |
| Q1 2025 | $7.2M | +138% |
| Q4 2024 | $5.2M | +59% |
CCCC's revenue is growing: $8M last quarter, down 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -290% | +16 points |
| Q2 2026 | -398% | +43 points |
| Q1 2026 | -452% | -49 points |
| Q4 2025 | -210% | +518 points |
| Q3 2025 | -306% | -123 points |
| Q2 2025 | -441% | -262 points |
| Q1 2025 | -403% | +657 points |
| Q4 2024 | -728% | +419 points |
CCCC's operating margin was −290% last quarter, up 16 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CCCC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CCCC on profitability, with a higher operating margin.
CCCC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26M | +$5.7M |
| Q1 2026 | -$30M | +$3.3M |
| Q4 2025 | -$22.2M | -$4.2M |
| Q1 2025 | -$33.3M | -$15.2M |
| Q4 2024 | -$17.9M | +$6.2M |
| Q1 2024 | -$18.1M | +$15.6M |
| Q4 2023 | -$24.2M | +$6.5M |
| Q1 2023 | -$33.7M | -$6.9M |
CCCC has burned cash in almost every quarter: −$80M over the past year, against −$101M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CCCC on cash generation, producing positive trailing cash flow while its opponent burns cash.
CCCC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +5.4M shares |
| 1 year | +88% | +63.5M shares |
| 3 years | +177% | +87M shares |
| 5 years | +210% | +92.2M shares |
| Available history | +690% | +119M shares |
CCCC has 136M diluted shares, up 88% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $39,000 |
| Q2 2026 | — |
| Q1 2026 | $200,000 |
| Q4 2025 | $14,000 |
| Q3 2025 | $24,000 |
| Q2 2025 | — |
| Q1 2025 | $155,000 |
| Q4 2024 | — |
CCCC has spent almost nothing on buybacks in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over CCCC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CCCC Net Leverage
CCCC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CCCC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 27.4 | Neutral |
CCCC's weekly RSI is 42 (neutral) and its Stochastic is 27 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CCCC PE vs Healthcare Sector
CCCC has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CCCC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.02 | 8.3% below |
| 20 week MA | $3.48 | 20% below |
| 50 week MA | $3.07 | 9.8% below |
| 100 week MA | $2.72 | 1.8% above |
| 200 week MA | $3.77 | 27% below |
CCCC's trend is mixed: it's above one of its five weekly moving averages, and 27% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CCCC on trend strength, trading above more of its moving averages.
CCCC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.5 | $35.4 | +39% |
| 2021 | $35.4 | $33.4 | -5.8% |
| 2022 | $33.4 | $6.08 | -82% |
| 2023 | $6.08 | $5.65 | -7.1% |
| 2024 | $5.65 | $3.79 | -33% |
| 2025 | $3.79 | $2.12 | -44% |
| 2026 YTD | $2.12 | $2.77 | +31% |
CCCC has finished five years in a row lower, and it's up 31% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CCCC on returns for 2026, with the stronger performance.